Role of KRAS in Colorectal Cancer
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (31 March 2019) | Viewed by 5613
Special Issue Editors
Interests: KRAS signaling pathway; autophagy; colorectal cancer (CRC); yeast model; molecular target
Special Issues, Collections and Topics in MDPI journals
Interests: oncogenic signaling; colorectal cancer; anti-tumor compounds or drugs
2. INEB–Instituto de Engenharia Biomédica, Universidade do Porto, 4200-135 Porto, Portugal
3. Departament of Pathology, Faculdade de Medicina, Universidade do Porto, 4200-319 Porto, Portugal
Interests: tumor microenvironment; tumor immunology; colorectal cancer; radiotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Colorectal cancer (CRC) is a leading cause of mortality in Europe, and its global therapeutics market is worth billions of Euros. KRAS-activating mutations (KRASm): KRASG13D, KRASG12D and KRASG12V are among the most frequent events found in CRC. Metastatic CRC harboring KRAS mutations are generally resistant to chemotherapy, namely to epidermal growth factor receptor (EGFR) inhibitors. This is a relevant clinical problem that urges a resolution. Despite the billions of dollars spent by pharmaceutical companies, so far, inhibition of mutated RAS has not been achieved.
The study of the role of KRAS mutations on colon carcinogenesis, tumor microenvironment, cell survival, autophagy, glycolytic metabolism and invasion/metastization potential is an ever-growing field. A precise understanding of the mechanisms underlying KRAS in colorectal carcinogenesis might help in identifying new molecular targets to overcome the resistance in CRC harboring KRAS mutations.
This Special Issue aims to highlight the most recent advances on the role of KRAS mutations on colorectal carcinogenesis using different cellular models and on their possible therapeutic applications.
We look forward to your contributions.
Dr. Ana Preto
Guest Editor
Dr. Sérgia Velho
Dr. Maria José Oliveira
Assistant Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- KRAS mutations
- colorectal cancer
- autophagy
- tumor microenvironment
- invasion/ metastasis
- glycolytic metabolism
- cell models
- therapeutic approaches
